UBS calls Auxilium a 'sleeper pick' for 2014 UBS believes investors are overlooking Auxilium's highly leveraged business model which will be driven by strong Xiaflex, Stendra, and Testopel growth, and stabilizing Testim. The firm expects operating margins to move towards 30% by 2016-17 from approximately 10% in 2013 and a pathway for 30% stock return performance over the next year. Shares are Buy rated with a $30 price target, up from $23.
Endo upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
Auxilium downgraded to Neutral from Buy at Mizuho Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.